209 related articles for article (PubMed ID: 7640231)
1. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2.
Gooding R; Riches P; Dadian G; Moore J; Gore M
Br J Cancer; 1995 Aug; 72(2):452-5. PubMed ID: 7640231
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin 2 receptors abrogate IL-2 induced activation of peripheral mononuclear cells.
Zorn U; Dallmann I; Grosse J; Kirchner H; Poliwoda H; Atzpodien J
Cytokine; 1994 Jul; 6(4):358-64. PubMed ID: 7948742
[TBL] [Abstract][Full Text] [Related]
3. Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells.
Paietta E; Nelson DL; Andersen J; Dutcher JP; Wiernik PH
Med Oncol; 1995 Jun; 12(2):121-4. PubMed ID: 8535662
[TBL] [Abstract][Full Text] [Related]
4. IL-2 regulation of soluble IL-2 receptor levels following thermal injury.
Teodorczyk-Injeyan JA; Sparkes BG; Lalani S; Peters WJ; Mills GB
Clin Exp Immunol; 1992 Oct; 90(1):36-42. PubMed ID: 1382903
[TBL] [Abstract][Full Text] [Related]
5. Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease.
Damle RN; Advani SH; Gangal SG
Int J Cancer; 1992 Jan; 50(2):192-6. PubMed ID: 1730512
[TBL] [Abstract][Full Text] [Related]
6. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
[TBL] [Abstract][Full Text] [Related]
7. Functional studies of soluble low-affinity interleukin-2 receptors in rheumatoid synovial fluid.
Miossec P; Elhamiani M; Edmonds-Alt X; Sany J; Hirn M
Arthritis Rheum; 1990 Nov; 33(11):1688-94. PubMed ID: 2242065
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of soluble interleukin-2 receptor in renal cell carcinoma.
Matsumoto T; Furukawa A; Sumiyoshi Y; Akiyama KY; Kanayama HO; Kagawa S
Urology; 1998 Jan; 51(1):145-9. PubMed ID: 9457310
[TBL] [Abstract][Full Text] [Related]
9. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
Elg SA; Hill RB; Heldman L; Ramakrishnan S
Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
[TBL] [Abstract][Full Text] [Related]
10. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
[TBL] [Abstract][Full Text] [Related]
11. [The role of serum soluble interleukin 2 receptor (sIL-2R) levels in patients with renal cell carcinoma].
Akiyama K; Tsuji M; Kurokawa Y; Yokota K; Kojima K; Naruo S; Kanayana HO; Kagawa S
Nihon Hinyokika Gakkai Zasshi; 1997 Apr; 88(4):473-8. PubMed ID: 9155114
[TBL] [Abstract][Full Text] [Related]
12. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
[TBL] [Abstract][Full Text] [Related]
13. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
14. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
Bodey B; Psenko V; Lipsey AL; Kaiser HE
Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the participation of interleukin-2 (IL-2) and IL-4 in the regulation of autonomous growth and tumorigenesis of transformed cells of lymphoid origin.
Hassuneh MR; Nagarkatti PS; Nagarkatti M
Blood; 1997 Jan; 89(2):610-20. PubMed ID: 9002965
[TBL] [Abstract][Full Text] [Related]
17. Release of sIL-2R alpha from and activation of native human peripheral blood mononuclear cells by recombinant IL-15.
Treiber-Held S; Stewart DM; Barraclough HA; Kurman CC; Nelson DL
Clin Immunol Immunopathol; 1996 Jul; 80(1):67-75. PubMed ID: 8674241
[TBL] [Abstract][Full Text] [Related]
18. Highly concentrated urine-purified Tac peptide fails to inhibit IL-2-dependent cell proliferation in vitro.
Pizzolo G; Vincenzi C; Vinante F; Rigo A; Veneri D; Chilosi M; Dusi S; Poli G; Zambello R; Semenzato G
Cell Immunol; 1992 Apr; 141(1):253-9. PubMed ID: 1555253
[TBL] [Abstract][Full Text] [Related]
19. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition.
Symons JA; Wood NC; Di Giovine FS; Duff GW
J Immunol; 1988 Oct; 141(8):2612-8. PubMed ID: 3262665
[TBL] [Abstract][Full Text] [Related]
20. Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo?
Dummer R; Posseckert G; Nestle F; Witzgall R; Burger M; Becker JC; Schäfer E; Wiede J; Sebald W; Burg G
J Invest Dermatol; 1992 Jan; 98(1):50-4. PubMed ID: 1728640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
